Cipla’s Novel Patent Suit Could Set Generics Precedent In India
This article was originally published in PharmAsia News
A patent fight between India's Cipla generics maker and Roche could have major consequences for generics makers. The case being considered by the Delhi high court involves Cipla launching a copy of Roche's Tarceva (erlotinib) even though the Swiss company had an Indian patent for the drug. Cipla reportedly intends to press a case the patent should not have been granted in the first place. Roche challenges Cipla's decision to launch a generic before getting a court ruling on the Roche patent, a novel approach in India. (Click here for more
You may also be interested in...
The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
The company will invest $1.2bn over the next four years to expand and upgrade its manufacturing capacity for pre-fillable syringes and advanced drug delivery systems across seven manufacturing facilities.